Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RARE vs XNCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Captures Overall Composite Edge (29.6 SELL vs 43.8 HOLD), While RARE Leads 4–2 on Growth & Valuation Pillars

XNCR Overall Winner 6-Pillar Tally: RARE 4 – 2 XNCR Matrix Metrics: RARE 4 – 6 XNCR

As of Nov 16, 2026, Xencor, Inc. (XNCR) captures the overall head-to-head institutional edge over Ultragenyx Pharmaceutical Inc. (RARE) on higher Unified Composite conviction (29.6/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while RARE wins 4–2 across the 6-pillar growth and valuation breakdown. RARE trades at $15.96 (11.2x Forward P/E, -59.9% operating margin) versus XNCR at $35.61 (68.0x Forward P/E, -72.7% operating margin).

  • Composite vs. Pillar Nuance: While RARE currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -59.9% operating margin) and revenue trajectory (+454.9% vs. +8.1% YoY).
  • Technical & Structure Timing Caution: RARE is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2); meanwhile XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RARE vs XNCR
RARE NASDAQ
Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations
$15.96
-0.78% 1D
Market Cap $1.7B
TTM Revenue $730M
Forward P/E 11.2x
Beta / 30D Vol 1.40β · 57% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 36.0 Fund 53.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -18.7%) with fading momentum, RSI 48
RSI-14: 48.2 · SMA20: $16.26 · SMA50: $15.30
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52

6-Pillar Scorecard Institutional Category Breakdown (RARE 4 – 2 XNCR)

Columns: Metric · RARE · XNCR
1. Valuation Multiples RARE
Forward P/E 11.2x 68.0x
Trailing P/E N/M 68.0x
PEG Ratio N/M N/M
EV / Revenue 2.3x 14.8x
2. Growth & Scale XNCR
Revenue Growth (YoY) +8.1% +454.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $730M $200M
Market Cap $1.7B $2.9B
3. Profitability & Quality RARE
Gross Margin -10.7% -42.5%
Operating Margin -59.9% -72.7%
Net Profit Margin -71.8% -58.8%
Return on Equity (ROE) -608.5% -19.9%
4. Balance Sheet & Cash Flow RARE
Cash Generation (TTM) -$447M -$176M
Cash Flow Margin -61.2% -88.0%
Net Cash / Leverage -608.5% ROE $101M Net Debt (0.29x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 171.9% (38th %ile) 79.0% (10th %ile)
Put/Call OI Skew 0.40x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution ACCUMULATION · Markup
6. R&D & Supply-Chain Moat RARE
OpEx & R&D Intensity 49.2% of Rev ($359M) 30.2% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RARE (4) vs XNCR (6)
Institutional Metric RARE XNCR Criterion Row Edge
Market Capitalization
Scale
$1.7B $2.9B Larger Scale XNCR
Trailing P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Forward P/E Ratio
Valuation
11.2x 68.0x Lower Multiple RARE
Revenue Growth (YoY)
Growth
+8.1% +454.9% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-59.9% -72.7% Higher Margin RARE
Net Profit Margin
Profitability
-71.8% -58.8% Higher Margin XNCR
Return on Equity (ROE)
Capital Efficiency
-608.5% -19.9% Higher ROE XNCR
52-Week Range Position
Momentum
12% ($13–$40) 84% ($10–$41) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.40β · 57% Vol 1.21β · 87% Vol Lower Realized Risk RARE
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite RARE
Trailing 12M Revenue (USD)
Operating Scale
$730M $200M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-10.7% -42.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 14.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$447M (-608.5% ROE) -$176M ($101M Net Debt (0.29x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +46.11 pp
RARE: +9.73% · XNCR: +55.84%
3M Horizon XNCR +77.55 pp
RARE: -37.41% · XNCR: +40.14%
6M Horizon XNCR +256.01 pp
RARE: -34.04% · XNCR: +221.97%
1Y Horizon XNCR +206.04 pp
RARE: -51.5% · XNCR: +154.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RARE Revenue XNCR Revenue RARE Op. Margin XNCR Op. Margin Margin Leader
FY2018 $50M $40M -721.2% -195.5% XNCR
FY2019 $100M $160M -409.0% 8.8% XNCR
FY2020 $270M $120M -121.8% -62.6% XNCR
FY2021 $350M $280M -108.6% 15.9% XNCR
FY2022 $360M $160M -178.6% -50.1% XNCR
FY2023 $430M $170M -131.1% -75.8% XNCR
FY2024 $560M $110M -95.7% -161.5% RARE
FY2025 $670M $130M -79.5% -141.4% RARE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RARE BREAKDOWN
93d in phase · OBV DISTRIBUTION
Current IV 171.9%
IV Percentile 38th %ile
Put/Call OI Skew 0.40x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact RARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -59.9% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($359M)
90D Engineering Disclosures 0 Published
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ RARE vs XNCR Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) captures the overall head-to-head institutional edge over Ultragenyx Pharmaceutical Inc. (RARE) on higher Unified Composite conviction (29.6/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while RARE wins 4–2 across the 6-pillar growth and valuation breakdown. RARE trades at $15.96 (11.2x Forward P/E, -59.9% operating margin) versus XNCR at $35.61 (68.0x Forward P/E, -72.7% operating margin). Composite vs. Pillar Nuance: While RARE currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -59.9% operating margin) and revenue trajectory (+454.9% vs. +8.1% YoY). Technical & Structure Timing Caution: RARE is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2); meanwhile XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: RARE posts +8.1% YoY revenue growth and +0.0% YoY earnings growth on $730M TTM revenue (-10.7% gross margin, -59.9% operating margin), compared with XNCR at +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RARE cumulative revenue shifted +1240.0% while XNCR shifted +225.0%. In operating R&D and SG&A reinvestment, RARE deploys 49.2% of Rev ($359M) (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($61M) (0 disclosures) for XNCR.

RARE screens cheaper on headline valuation multiples. RARE trades at 11.2x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-61.2% FCF margin), whereas XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RARE (-608.5% ROE) versus XNCR (-19.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RARE carries 171.9% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 57% Vol realized risk). By comparison, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.